BrightHeart raises €11m to drive AI heart defect detection platform adoption
BrightHeart’s AI-based CHD detection platform received FDA clearance in 2024 and is currently being used at a limited range of US facilities.
09 January 2026
09 January 2026
BrightHeart’s AI-based CHD detection platform received FDA clearance in 2024 and is currently being used at a limited range of US facilities.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.